Gene: SOX17

64321
VUR3
SRY-box 17
protein-coding
8q11.23
Ensembl:ENSG00000164736 MIM:610928 Vega:OTTHUMG00000164377 UniprotKB:Q9H6I2
NG_028171.1
PubMed
0   ANCO-SNPs
ND
3   
NA (AD)  NA (ND)   (Frontal_Cortex)
8.403e-1 (AD)  3.254e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
LSR0.742
CHMP4C0.705
RAMP20.687
CLEC14A0.683
FOXC20.683
PGM50.682
USHBP10.681
SEMA3G0.675
TMEM2040.672
TIE10.665

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
HTR1E-0.304
GALNT14-0.302
KCNB2-0.294
DRD5-0.292
HCRTR2-0.287
MARCH11-0.285
MMP16-0.28
B3GALT2-0.28
MUM1L1-0.275
TENM3-0.274

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in increased expression of SOX17 mRNA"25614096
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane affects the expression of SOX17 mRNA"18648102
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide results in decreased localization of SOX17 protein"24154490
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX17 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine results in decreased localization of SOX17 protein"24154490
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX17 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of SOX17 mRNA22230336
D000082AcetaminophenAcetaminophen affects the expression of SOX17 mRNA17562736
D019342Acetic AcidAcetic Acid results in decreased expression of SOX17 protein21296659
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of SOX17 mRNA22100608
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of SOX17 gene27153756
D0151206-Aminonicotinamide6-Aminonicotinamide results in decreased localization of SOX17 protein24154490
C015001arsenitearsenite results in increased methylation of SOX17 promoter23974009
C030935benz(a)anthracenebenz(a)anthracene results in increased expression of SOX17 mRNA26377693
C030935benz(a)anthracene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SOX17 mRNA27858113
C006703benzo(b)fluoranthene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SOX17 mRNA27858113
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in increased expression of SOX17 mRNA26377693
C022921benzo(k)fluoranthenebenzo(k)fluoranthene results in increased expression of SOX17 mRNA26377693
D001564Benzo(a)pyrene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SOX17 mRNA27858113
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of SOX17 mRNA19770486|2222880
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of SOX17 mRNA21839799
D004958EstradiolESR1 protein promotes the reaction [Estradiol results in decreased expression of SOX17 mRNA]25210133
D004958EstradiolEstradiol results in decreased expression of SOX17 mRNA25210133
C006780bisphenol Abisphenol A results in increased expression of SOX17 mRNA27271280
C006780bisphenol Abisphenol A results in increased expression of SOX17 mRNA24090592
C006780bisphenol Abisphenol A results in decreased expression of SOX17 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of SOX17 gene28505145
C099813bromochloroacetic acidbromochloroacetic acid results in decreased expression of SOX17 protein21296659
D001973BromodeoxyuridineBromodeoxyuridine results in decreased localization of SOX17 protein24154490
C018475butyraldehydebutyraldehyde results in increased expression of SOX17 mRNA26079696
D002220CarbamazepineCarbamazepine affects the expression of SOX17 mRNA25979313
C004662chlorophacinonechlorophacinone results in decreased localization of SOX17 protein24154490
D002737ChloropreneChloroprene results in decreased expression of SOX17 mRNA23125180
C031180chrysene[Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in decreased expression of SOX17 mRNA27858113
C055786columbaminecolumbamine results in decreased expression of SOX17 mRNA23124089
D003471CuprizoneCuprizone affects the expression of SOX17 mRNA27523638
D003471CuprizoneCuprizone results in decreased expression of SOX17 mRNA26577399
D003609DactinomycinDactinomycin results in decreased localization of SOX17 protein24154490
D000069439DasatinibDasatinib results in decreased localization of SOX17 protein24154490
C014347decitabinedecitabine results in decreased methylation of SOX17 promoter18413743
C014347decitabinedecitabine results in increased expression of SOX17 mRNA18413743
C014347decitabinedecitabine results in increased expression of SOX17 protein18413743
C036042dicyclohexyl phthalatedicyclohexyl phthalate affects the expression of SOX17 mRNA26924002
D004051Diethylhexyl Phthalate[Diethylhexyl Phthalate co-treated with Genistein] results in decreased expression of SOX17 mRNA25031359
D004052DiethylnitrosamineDiethylnitrosamine results in decreased expression of SOX17 mRNA21527772
D004054DiethylstilbestrolDiethylstilbestrol results in decreased localization of SOX17 protein24154490
D004054DiethylstilbestrolDiethylstilbestrol results in increased expression of SOX17 mRNA19371625
C024629dimethyl phthalatedimethyl phthalate affects the expression of SOX17 mRNA26924002
D004121Dimethyl SulfoxideDimethyl Sulfoxide results in decreased expression of SOX17 mRNA22105179
C049346diniconazolediniconazole results in decreased localization of SOX17 protein24154490
C018527dinosebdinoseb results in decreased localization of SOX17 protein24154490
D004178DiquatDiquat results in decreased localization of SOX17 protein24154490
D004317DoxorubicinDoxorubicin results in decreased localization of SOX17 protein24154490
D004997Ethinyl EstradiolEthinyl Estradiol results in decreased expression of SOX17 mRNA23550701
C075780fluazinamfluazinam results in decreased localization of SOX17 protein24154490
D005472FluorouracilFluorouracil results in decreased localization of SOX17 protein24154490
D005472FluorouracilFluorouracil results in decreased expression of SOX17 protein21296659
C061365flusilazoleflusilazole results in decreased localization of SOX17 protein24154490
C069837fullerene C60fullerene C60 results in increased expression of SOX17 mRNA19167457
C419708gefitinibgefitinib results in decreased localization of SOX17 protein24154490
D019833Genistein[Diethylhexyl Phthalate co-treated with Genistein] results in decreased expression of SOX17 mRNA25031359
C409722hexaconazolehexaconazole results in decreased localization of SOX17 protein24154490
D017313FenretinideFenretinide results in increased expression of SOX17 mRNA28973697
D000068877Imatinib MesylateImatinib Mesylate results in decreased localization of SOX17 protein24154490
C041508indeno(1,2,3-cd)pyrene"indeno(1,2,3-cd)pyrene results in decreased expression of SOX17 mRNA"26377693
D007545IsoproterenolIsoproterenol results in increased expression of SOX17 mRNA20003209
D008070LipopolysaccharidesLipopolysaccharides results in increased expression of SOX17 mRNA10975854
C030272maleic acidmaleic acid results in increased expression of SOX17 mRNA28392987
D008694Methamphetamine[Methamphetamine co-treated with SCH 23390] results in decreased expression of SOX17 mRNA19564919
D008694MethamphetamineMethamphetamine results in decreased expression of SOX17 mRNA19564919
D008748Methylcholanthrene[Methylcholanthrene co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of SOX17 mRNA23519560
D008803MianserinMianserin results in decreased localization of SOX17 protein24154490
D015735MifepristoneMifepristone results in decreased expression of SOX17 mRNA25972201
C517284monomethyl phthalatemonomethyl phthalate affects the expression of SOX17 mRNA26924002
C452423N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amineN-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine results in decreased localization of SOX17 protein24154490
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of SOX17 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of SOX17 mRNA"25554681
C031721naphthalenenaphthalene results in increased expression of SOX17 protein16239640
C025256nonylphenolnonylphenol results in decreased expression of SOX17 mRNA22982499
C030110oxaliplatin[oxaliplatin co-treated with Topotecan] results in increased expression of SOX17 mRNA25729387
D010269ParaquatParaquat results in increased expression of SOX17 mRNA12595580
C076994perfluorooctane sulfonic acidperfluorooctane sulfonic acid results in decreased expression of SOX17 mRNA25510869
D010634PhenobarbitalPhenobarbital affects the expression of SOX17 mRNA23091169
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX17 mRNA"27188386
D011441PropylthiouracilPropylthiouracil results in decreased expression of SOX17 mRNA24780913
C059514resveratrolresveratrol results in decreased expression of SOX17 mRNA19371625
C059514resveratrolresveratrol results in decreased expression of SOX17 mRNA25905778
D015474IsotretinoinIsotretinoin results in decreased localization of SOX17 protein24154490
D016713RitanserinRitanserin results in decreased localization of SOX17 protein24154490
C534628SCH 23390[Methamphetamine co-treated with SCH 23390] results in decreased expression of SOX17 mRNA19564919
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of SOX17 mRNA25895662
D053260SootSoot results in decreased expression of SOX17 mRNA26551751
C471405sorafenibsorafenib results in decreased localization of SOX17 protein24154490
C473478sunitinibsunitinib results in decreased localization of SOX17 protein24154490
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of SOX17 mRNA26377647
D013749Tetrachlorodibenzodioxin[Tetrachlorodibenzodioxin co-treated with TIPARP gene mutant form] results in increased expression of SOX17 mRNA25975270
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of SOX17 mRNA19770486|2405805
D013750TetrachloroethyleneTetrachloroethylene results in decreased expression of SOX17 mRNA28973375
D013755Tetradecanoylphorbol Acetate[Methylcholanthrene co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of SOX17 mRNA23519560
D013792ThalidomideThalidomide results in decreased localization of SOX17 protein24154490
C009495titanium dioxidetitanium dioxide results in increased expression of SOX17 mRNA23557971
D014050TolueneToluene results in increased expression of SOX17 mRNA22967744
D019772Topotecan[oxaliplatin co-treated with Topotecan] results in increased expression of SOX17 mRNA25729387
D014212TretinoinTretinoin results in decreased localization of SOX17 protein24154490
D014212TretinoinTretinoin results in increased expression of SOX17 mRNA16236135
D014241TrichloroethyleneTrichloroethylene results in decreased expression of SOX17 mRNA28013219
D014241TrichloroethyleneTrichloroethylene results in decreased methylation of SOX17 gene27618143
C012589trichostatin Atrichostatin A results in increased expression of SOX17 mRNA15901671
C015559trimellitic anhydridetrimellitic anhydride results in decreased expression of SOX17 mRNA19042947
D014635Valproic AcidValproic Acid affects the expression of SOX17 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased localization of SOX17 protein24154490
D014635Valproic AcidValproic Acid results in increased expression of SOX17 mRNA15901671
C025643vinclozolinvinclozolin affects the expression of SOX17 mRNA19015723
C029297vinylidene chloridevinylidene chloride results in decreased expression of SOX17 mRNA26682919
D014801Vitamin A[Vitamin A co-treated with INHBA protein] results in increased expression of SOX17 mRNA17244017
D002762CholecalciferolCholecalciferol results in increased expression of SOX17 mRNA17170073
D002762CholecalciferolCholecalciferol results in increased expression of SOX17 protein17170073
C092292ziprasidoneziprasidone results in decreased localization of SOX17 protein24154490
C088658zoledronic acidzoledronic acid results in increased expression of SOX17 mRNA24714768

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-IBA21873635  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISA-  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISM19274049  
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-NAS19274049  
GO:0001228transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding-IBA21873635  
GO:0001228transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding-IEA-  
GO:0003705transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding-ISS-  
GO:0003713transcription coactivator activity-IEA-  
GO:0005515protein binding-IPI17875931  
GO:0008013beta-catenin binding-IPI17875931  
GO:0008134transcription factor binding-IPI17875931  19736317  
GO:0043565sequence-specific DNA binding-IEA-  
GO:0044212transcription regulatory region DNA binding-ISS-  
GO:0046982protein heterodimerization activity-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000122negative regulation of transcription by RNA polymerase II-IBA21873635  
GO:0000122negative regulation of transcription by RNA polymerase II-IEA-  
GO:0001525angiogenesis-IBA21873635  
GO:0001525angiogenesis-ISS-  
GO:0001568blood vessel development-IBA21873635  
GO:0001570vasculogenesis-IBA21873635  
GO:0001570vasculogenesis-ISS-  
GO:0001706endoderm formation-IDA18682240  
GO:0001828inner cell mass cellular morphogenesis-IEA-  
GO:0001947heart looping-ISS-  
GO:0003142cardiogenic plate morphogenesis-ISS-  
GO:0003143embryonic heart tube morphogenesis-ISS-  
GO:0003151outflow tract morphogenesis-ISS-  
GO:0003308negative regulation of Wnt signaling pathway involved in heart development-IEA-  
GO:0006355regulation of transcription, DNA-templated-IBA21873635  
GO:0006355regulation of transcription, DNA-templated-ISS-  
GO:0007283spermatogenesis-IEA-  
GO:0007493endodermal cell fate determination-IEA-  
GO:0007507heart development-IBA21873635  
GO:0009653anatomical structure morphogenesis-IBA21873635  
GO:0021903rostrocaudal neural tube patterning-IEA-  
GO:0023019signal transduction involved in regulation of gene expression-IEA-  
GO:0030154cell differentiation-IBA21873635  
GO:0030308negative regulation of cell growth-IMP18413743  
GO:0031648protein destabilization-IMP17875931  
GO:0035050embryonic heart tube development-ISS-  
GO:0042074cell migration involved in gastrulation-IEA-  
GO:0042662negative regulation of mesodermal cell fate specification-IEA-  
GO:0042789mRNA transcription by RNA polymerase II-IDA22292085  
GO:0045597positive regulation of cell differentiation-IEA-  
GO:0045732positive regulation of protein catabolic process-IEA-  
GO:0045893positive regulation of transcription, DNA-templated-ISS-  
GO:0045944positive regulation of transcription by RNA polymerase II-IBA21873635  
GO:0045944positive regulation of transcription by RNA polymerase II-IDA22292085  
GO:0045995regulation of embryonic development-ISS-  
GO:0048617embryonic foregut morphogenesis-ISS-  
GO:0048643positive regulation of skeletal muscle tissue development-IEA-  
GO:0048866stem cell fate specification-IEA-  
GO:0050821protein stabilization-IMP17875931  
GO:0060070canonical Wnt signaling pathway-IEA-  
GO:0060214endocardium formation-ISS-  
GO:0060807regulation of transcription from RNA polymerase II promoter involved in definitive endodermal cell fate specification-ISS-  
GO:0060913cardiac cell fate determination-IMP19736317  
GO:0060914heart formation-TAS19736317  
GO:0060956endocardial cell differentiation-ISS-  
GO:0061009common bile duct development-IEA-  
GO:0061010gall bladder development-IEA-  
GO:0061031endodermal digestive tract morphogenesis-ISS-  
GO:0072001renal system development-IMP20960469  
GO:0072091regulation of stem cell proliferation-IEA-  
GO:0090090negative regulation of canonical Wnt signaling pathway-IMP18413743  20960469  
GO:1990830cellular response to leukemia inhibitory factor-IEA-  
GO:2000035regulation of stem cell division-IEA-  
GO:2000043regulation of cardiac cell fate specification-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-IBA21873635  
GO:0005634nucleus-IDA17875931  18682240  
GO:0005654nucleoplasm-TAS-  
GO:0005667transcription factor complex-IDA19736317  
GO:0044798nuclear transcription factor complex-IBA21873635  
GO:0044798nuclear transcription factor complex-IEA-  
KEGG ID KEGG Term
hsa04310Wnt signaling pathway
Reactome ID Reactome Term Evidence
R-HSA-162582Signal TransductionTAS
R-HSA-195721Signaling by WNTTAS
R-HSA-201681TCF dependent signaling in response to WNTTAS
R-HSA-3769402Deactivation of the beta-catenin transactivating complexTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
22961961Genome-wide association study of intracranial aneurysms confirms role of Anril and SOX17 in disease risk. (2012 Nov)Foroud TStroke
28761511Genetic associations of intracranial aneurysm formation and sub-arachnoid hemorrhage. (2017 Jul-Sep)Theodotou CBAsian J Neurosurg
27110300The detective, prognostic, and predictive value of DNA methylation in human esophageal squamous cell carcinoma. (2016)Ma KClin Epigenetics